Head-To-Head Analysis: Scienture (NASDAQ:SCNX) vs. Ensysce Biosciences (NASDAQ:ENSC)

Ensysce Biosciences (NASDAQ:ENSC) and Scienture (NASDAQ:SCNX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends.

Volatility & Risk

Ensysce Biosciences has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Scienture has a beta of 3.25, meaning that its stock price is 225% more volatile than the S&P 500.

Earnings & Valuation

This table compares Ensysce Biosciences and Scienture”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07 million	1.58	-$10.18 million	($2.76)	-0.15
Scienture	$430,000.00	26.49	-$41.51 million	($2.10)	-0.13

Ensysce Biosciences has higher revenue and earnings than Scienture. Ensysce Biosciences is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ensysce Biosciences and Scienture’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-280.53%	-2,550.30%	-320.49%
Scienture	N/A	-53.51%	-42.47%

Institutional and Insider Ownership

5.6% of Ensysce Biosciences shares are held by institutional investors. Comparatively, 5.7% of Scienture shares are held by institutional investors. 2.8% of Ensysce Biosciences shares are held by insiders. Comparatively, 21.4% of Scienture shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Ensysce Biosciences and Scienture, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1	0	0	0	1.00
Scienture	1	0	1	0	2.00

Scienture has a consensus target price of $1.50, indicating a potential upside of 440.74%. Given Scienture’s stronger consensus rating and higher possible upside, analysts plainly believe Scienture is more favorable than Ensysce Biosciences.

Summary

Scienture beats Ensysce Biosciences on 12 of the 14 factors compared between the two stocks.

About Ensysce Biosciences

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

About Scienture

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.